Chronic & Non-communicable Diseases
Medical Treatment & Drug Development
AXA Chairs
Greece
Exploring Epigenetics : an extraordinarily promising field of medicine
Unravelling the complex mechanisms that govern gene expression
"We are at the dawn of a new age of genomic medicine", Dr. Iannis Talianadis points out. "If we want to fully reap the benefits of genomics for human health, there is a growing realization that knowledge of DNA must be complemented by a detailed understanding of how gene expression is controlled". The aim of the AXA Chair on Epigenetics is precisely to shed light on this crucial biological mechanisms, whose true nature remains largely obscure. Indeed, during his previous work, Dr. Iannis Talianadis found that the mechanisms behind epigenetic modifiers were more complex than was previously thought. These findings opened new avenues in the field of epigenetic control with the potential to generate transforming discoveries. With the AXA Chair on Epigenetics, Dr. Iannis Talianadis aims to further investigate the newly found regulatory mechanisms he uncovered in order to obtain a more comprehensive picture. Along with the team of promising researchers he pulled together, they will study these processes in normal physiological conditions and under disease conditions. Their focus will be on two age-related diseases in particular, metabolic syndrome and liver cancer, whose link with epigenetics have been established.
By developing a leading research division devoted to explore new avenues in the epigenetics basis of liver cancer and metabolic syndrome, Dr. Talianadis' research will contribute to the development of innovative therapeutical tools for the benefit of patients suffering from these diseases. His findings will have tremendous implications for genetic medicine in general, providing insight into largely unchartered but crucial territory. Moreover, the objective of the AXA Chair in Epigenetics will also be to build up the next generation of epigenetics researchers and to raise public awareness about the importance and potential of the field.

Iannis
TALIANIDIS
Institution
Institute of Molecular Biology and Biotechnology
Country
Greece
Nationality
Greek
Related articles
Chronic & Non-communicable Diseases
Medical Treatment & Drug Development
AXA Project
France
Pain Pediatric & Elderly AXA Research Lab (PEARL)
Cutaneous neuropathic pain is a highly debilitating chronic condition, characterized by persistent sensations of burning, tingling, or hypersensitivity. It disproportionately... Read more
Celine
GRECO
Hôpital Necker-Enfants Malades
Medical Treatment & Drug Development
Mécénat des Mutuelle
France
Accelerating drug innovation with the Euridis school and its DDD Challenge
The project addresses a dual challenge: on one hand, the increasing complexity of drug development, which requires a thorough understanding... Read more

Laurence
SABATIER
Institut du médicament de Strasbourg
Medical Treatment & Drug Development
Mécénat des Mutuelle
France
New Molecule to Combat Antibiotic-Resistant Childhood Sepsis
The global spread of antibiotic resistance requires the identification of new bacterial drug targets, the design and synthesis of innovative... Read more

Nalini
RAMA RAO